Outcomes of the Gore Excluder abdominal aortic aneurysm leg endoprosthesis for treatment of central vein stenosis or occlusion in patients with chronic hemodialysis

Chen, Yen-Yang; Wu, Chung-Kuan; Lin, Chia‐Hsun

doi:10.1016/j.jvsv.2019.08.017

Cited by 5 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stent graft can decrease the incidence of stenosis by providing a barrier to the surrounding fibrotic recoil of the vein and intimal hyperplasia, the central portion of the stent graft is less likely to show intimal hyperplasia. 16,20 In this study, the recurrent stenosis observed in SG group occurred within 0.5 cm of the edge of the stent graft. The balloon notch appeared at the edge of the stent graft during the balloon dilatation.…”

Section: Discussionmentioning

confidence: 59%

“…Kundu et al 19 reported a primary patency rate of 100% at 9 months of SGs in 14 patients on hemodialysis with CVD. Chen et al 20 reported a primary patency rate of 88.3% at 12 months of Gore Excluder AAA contralateral leg or iliac extender SGs in 60 patients.…”

Section: Discussionmentioning

confidence: 99%

“…These brachiocephalic vein and superior vena cava lesions are relatively straight and with low requirements for the flexibility of the stent, requiring a stent with a diameter of at least 14–16 mm. Chen et al 20 have reported remarkable target lesion patency rates (>80% at 24 months) in 60 patients treated with Gore Excluder iliac stent grafts. They have pointed out the size of the central vein is larger in diameter at the proximal segments close to the heart but smaller at the distal segments, iliac stent grafts can accommodate vein segments with different proximal and distal diameters and of various diameters and lengths.…”

Section: Discussionmentioning

confidence: 99%

“…They have pointed out the size of the central vein is larger in diameter at the proximal segments close to the heart but smaller at the distal segments, iliac stent grafts can accommodate vein segments with different proximal and distal diameters and of various diameters and lengths. 20 Therefore, the most suitable stent graft for CVD depends on the diameter, location and other characteristics of the lesion. To choose suitable stents, the operator should be familiar with the morphology of the lesions and the characteristics of the stents.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of stent grafts for treatment of central venous disease in hemodialysis patients

et al. 2022

View full text Add to dashboard Cite

Background: To evaluate the effectiveness of stent graft (SG) for the treatment of central venous disease (CVD) in hemodialysis patients. Methods: Between January 2014 and April 2022, 122 patients on hemodialysis with symptomatic CVD were treated with percutaneous transluminal angioplasty (PTA) and bare-metal stent (BMS) or SG placement. The mean follow-up was 14.5 months (IQR: 8.0, 24.2). Patency rates of the target sites were calculated using Kaplan-Meier and log-rank studies. Multivariate Cox proportional hazard models were used to evaluate the association between various characteristics and target site primary patency. Results: Technical success rate was 100%. At 3, 6, 12, and 24 months, the target sites primary patency rates were 86.4%, 74.2%, 45.1%, and 30.4% for PTA; 94.7%, 78.6%, 60.8%, and 45.6% for BMS; and 94.0%, 92.0%, 82.4%, and 66.8% for SG, respectively, and the assisted primary patency rates were 86.5%, 80.4%, 63.8%, and 46.0% for PTA; 94.7%, 89.5%, 77.5%, and 71.1% for BMS; 100%, 100%, 97.8%, and 83.4% for SG, respectively. The Kaplan–Meier analysis indicated that SGs achieved better primary and assisted primary patency than PTA or BMS ( p<0.05). SG use and concomitant stenosis were the independent predictors of target site primary patency dysfunction in the multivariate analysis. Conclusions: This study confirmed the better long-term patency of SG in comparison with PTA and BMS for the treatment of CVD in hemodialysis patients.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes of stent grafts for treatment of central venous disease in hemodialysis patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The TLPP at 6, 12, and 24 months post-SG placement was 91.3%, 67.6%, and 44.5%, respectively. A previous cohort study that included 60 cases with Excluder SGs for CVOD found that ACPP was 54.9% and TLPP was 88.3% at 12 months [23] . Another study showed that TLPP and ACPP with SGs for CVOD at 12 months were 56% and 29% [21] .…”

Section: Discussionmentioning

confidence: 95%

Clinical outcomes and predictive factors of stent grafts treatment for symptomatic central venous obstruction in end stage kidney disease patients with arteriovenous access

liu,

wang,

wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Aim To assess the effectiveness and predictive factors of stent grafts (SGs) for the treatment of central venous obstruction disease (CVOD) in hemodialysis (HD) patients with arteriovenous (AV) access. Methods HD patients with CVOD who underwent SGs at our center between August 2018 and June 2022 were enrolled. The Kaplan–Meier method and log-rank test were used for survival curve analysis. SGs. Results 59 SG implantation procedures for CVOD were analyzed using Cox proportional hazards regression for the predictive factor analysis. Thirty subjects had stenosis and 29 had occlusion. The access circuit primary patency (ACPP) after SG placement at 6, 12, and 24 months was 80.9%, 53.8%, and 31.4%, respectively. The target lesion primary patency (TLPP) after SG placement at 6, 12, and 24 months were 91.3%, 67.6%, and 44.5%, respectively. In the subgroup analysis, the TLPP was higher in the stenosis group than in the occlusion group, but the difference was not significant (P = 0.165). The TLPP of procedures post-SG placement was significantly improved compared to that before SG placement (P < 0.001). Cox proportional hazards regression showed that a target lesion length ≥ 30 mm and procedural defects were independently associated with a lower TLPP after SG treatment for CVOD in HD patients. Conclusion SG placement is safe and effective for the treatment of CVOD in HD patients. SG improves the TLPP of endovascular therapy (EVT) for CVOD. A target lesion length ≥ 30 mm and procedure defects were predictive factors for TLPP.

show abstract

Management of Central Venous Stenoses and Occlusions

Kitrou

Κατσάνος

Karnabatidis

2023

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Symptomatic central venous stenosis and occlusion remains the gordian knot of vascular access. Advances in techniques, like sharp recanalization, allowed for improved success rates in crossing these difficult lesions. There is also increasing evidence of new devices in treating central venous stenosis and, at the same time, improving the time needed between interventions. High-pressure balloons, paclitaxel-coated balloons, bare metal stents and covered stents have been tested with an aim to offer additional treatment options, although obstacles still exist. In the current review, authors describe relevant techniques and options, provide the evidence and evaluate the actual implementation of these devices in this demanding field.

show abstract

Outcomes of the Gore Excluder abdominal aortic aneurysm leg endoprosthesis for treatment of central vein stenosis or occlusion in patients with chronic hemodialysis

Cited by 5 publications

References 20 publications

Outcomes of stent grafts for treatment of central venous disease in hemodialysis patients

Outcomes of stent grafts for treatment of central venous disease in hemodialysis patients

Clinical outcomes and predictive factors of stent grafts treatment for symptomatic central venous obstruction in end stage kidney disease patients with arteriovenous access

Management of Central Venous Stenoses and Occlusions

Contact Info

Product

Resources

About